Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) EPS (Weighted Average and Diluted): 2014-2025

Historic EPS (Weighted Average and Diluted) for Lineage Cell Therapeutics (LCTX) over the last 11 years, with Sep 2025 value amounting to -$0.13.

  • Lineage Cell Therapeutics' EPS (Weighted Average and Diluted) fell 550.00% to -$0.13 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.29, marking a year-over-year decrease of 141.67%. This contributed to the annual value of -$0.09 for FY2024, which is 25.00% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported EPS (Weighted Average and Diluted) of -$0.13 as of Q3 2025, which was down 0.00% from -$0.13 recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' EPS (Weighted Average and Diluted) ranged from a high of -$0.01 in Q4 2024 and a low of -$0.13 during Q2 2025.
  • For the 3-year period, Lineage Cell Therapeutics' EPS (Weighted Average and Diluted) averaged around -$0.05, with its median value being -$0.03 (2024).
  • In the last 5 years, Lineage Cell Therapeutics' EPS (Weighted Average and Diluted) surged by 83.33% in 2021 and then slumped by 550.00% in 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.05 in 2021, then increased by 20.00% to -$0.03 in 2022, then remained steady at -$0.03 in 2023, then surged by 66.67% to -$0.01 in 2024, then crashed by 550.00% to -$0.13 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at -$0.13 for Q3 2025, versus -$0.13 for Q2 2025 and -$0.02 for Q1 2025.